remsima truxima herzuma yuflyma
Scope
Date
~
-
Bio & PharmaCelltrion's Remsima receives approval in 100 countries in 10 years
South Korea's most valuable biopharmaceutical company Celltrion Inc. said on Tuesday that its antibody biosimilar Remsima (ingredient: infliximab) h...
Jan 03, 2023 (Gmt+09:00)
-
Bio & PharmaKOICA donates Celltrion's Herzuma to Ukraine
Celltrion Healthcare Co. said on Monday that Herzuma (ingredient name: Trastuzumab) was dispatched to patients in Ukraine by the Korea International...
Dec 26, 2022 (Gmt+09:00)
-
Bio & PharmaCelltrion applies for FDA approval for Remsima SC
Celltrion Ltd. said on Friday it had applied the previous day for permission from the US Food and Drug Administration (FDA) for Remsima SC, an autoi...
Dec 23, 2022 (Gmt+09:00)
-
Bio & PharmaCelltrion to seek FDA approval for sale of Remsima SC by year-end
Celltrion Inc. said it has confirmed the effectiveness and safety of Remsima SC in its third-phase global clinical trials, conducted on 438 patients...
Nov 28, 2022 (Gmt+09:00)
-
EarningsCelltrion's Q3 earnings boosted by Remsima sales in Europe
South Korean biopharmaceutical giant Celltrion Inc. announced 654.6 billion won ($478.2 million) in revenue and 213.8 billion won in operating profi...
Nov 09, 2022 (Gmt+09:00)
-
Bio & PharmaCelltrion Healthcare logs record-high Q2 revenue on back of Remsima
Celltrion Healthcare Co., South Korean biopharmaceutical giant Celltrion Inc.’s global marketing affiliate, posted its record-high second-quar...
Aug 17, 2022 (Gmt+09:00)
Latest News
- 1 Seoul appeal: Korean art captivates Indonesia’s affluent connoisseurs
- 2 CJ CheilJedang scraps $3.5 bn green bio sale, shifts gears to expansion
- 3 Trump Jr. meets Korean business chiefs in back-to-back sessions
- 4 Samsung in talks to supply customized HBM4 to Nvidia, Broadcom, Google
- 5 Kookmin Bank raises $700 mn in forex bonds amid strong demand
